Design, synthesis, and biological evaluation of novel N-(1H-indazol-6-yl)benzenesulfonamide derivatives as potent PLK4 inhibitors

Abstract

PLK4 is a serine/threonine protein kinase situated at the centrosome, acting as a crucial regulatory element in the regulation of cell mitosis and significantly contributing to the preservation of genomic integrity. The overexpression of PLK4 is intricately linked to the onset and progression of several cancers, influencing a range of actions in tumor cells, such as proliferation, differentiation, migration, and invasion. PLK4 has been identified as a target for the therapy of several malignancies, especially breast cancer characterized by elevated TRIM37 levels. Consequently, the development of safe, efficient, and highly selective PLK4 inhibitors is of considerable importance. This study examined existing PLK4 inhibitors, chose N-(1H-indazol-6-yl)benzenesulfonamide as the core structure, and synthesized a series of extremely effective PLK4 inhibitors by structural simplification and fragment growth methodologies. In vitro enzyme activity studies demonstrated that compound K22 has significant PLK4 inhibitory activity (IC50 = 0.1 nM). K22 demonstrated significant anti-proliferative efficacy against MCF-7 breast cancer cells at the cellular level (IC50 = 1.3 μM). Moreover, PLK4 inhibitor K22 showed acceptable human liver microsome stability (T1/2 = 51.0 min). In the pharmacokinetic study, compound K22 exhibited a good area under the curve (AUC0−t = 447 ± 47.6 ng h mL−1) and acceptable half-life (T1/2 = 1.07 ± 0.111 h). In summary, compound K22 has further research value as a PLK4 inhibitor.

Graphical abstract: Design, synthesis, and biological evaluation of novel N-(1H-indazol-6-yl)benzenesulfonamide derivatives as potent PLK4 inhibitors

Supplementary files

Article information

Article type
Research Article
Submitted
21 Mar 2025
Accepted
13 May 2025
First published
13 May 2025

RSC Med. Chem., 2025, Advance Article

Design, synthesis, and biological evaluation of novel N-(1H-indazol-6-yl)benzenesulfonamide derivatives as potent PLK4 inhibitors

P. Sun, C. Fan, N. Liu, M. Tong, X. Shi, H. Wang, S. Mu, N. Hu, Y. Sun, H. Zhang, Z. Gao, D. Zhao and M. Cheng, RSC Med. Chem., 2025, Advance Article , DOI: 10.1039/D5MD00251F

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements